SU-FF-T-435: Use of a Two-Dimensional Ionization Chamber Array for Proton Therapy Quality Assurance Checks

2007 ◽  
Vol 34 (6Part14) ◽  
pp. 2502-2502
Author(s):  
B Arjomandy ◽  
N Sahoo ◽  
M Gillin ◽  
X Zhu
2008 ◽  
Vol 35 (9) ◽  
pp. 3889-3894 ◽  
Author(s):  
Bijan Arjomandy ◽  
Narayan Sahoo ◽  
Xiaoning Ding ◽  
Michael Gillin

2015 ◽  
Vol 16 (3) ◽  
pp. 270-276 ◽  
Author(s):  
Liyong Lin ◽  
Minglei Kang ◽  
Timothy D. Solberg ◽  
Thierry Mertens ◽  
Christian Baumer ◽  
...  

2017 ◽  
Vol 44 ◽  
pp. 41
Author(s):  
N. Wanko ◽  
M. Vidal ◽  
A. Gérard ◽  
J. Hérault

2005 ◽  
Vol 32 (6Part8) ◽  
pp. 1982-1982
Author(s):  
B Poppe ◽  
A Blechschmidt ◽  
A Djouguela ◽  
R Kollhoff ◽  
A Rubach ◽  
...  

2017 ◽  
Vol 777 ◽  
pp. 012015 ◽  
Author(s):  
A H Merchant ◽  
S Guatelli ◽  
M Petesecca ◽  
M Jackson ◽  
A B Rozenfeld

Author(s):  
Pei-Ying Yang ◽  
Yang-Wei Hsieh ◽  
Chen-Lin Kang ◽  
Chin-Dar Tseng ◽  
Chih-Hsueh Lin ◽  
...  

This study utilized a new type of detector, the CROSS II (Liverage Biomedical Inc., Taiwan), to perform a beam quality assurance (QA) procedure on a Sumitomo (Sumitomo Heavy Industries, Inc., Japan) pencil beam linear scanning proton therapy machine. The Cross II can monitor proton Pristine Bragg peak range, beam width, beam size, beam position, and scanning speed. All the data presented here were collected during a time span of over one year. The accuracy of the QA program could be verified if all the QA items were tested stably and within the programmed tolerances. Our results showed that the proton range remained within the [Formula: see text] mm tolerance, with the majority of measurements within [Formula: see text] mm, [Formula: see text] mm for spot size, 1.5 mm for spot position, and [Formula: see text]% for scanning speed. We found that the CROSS II detector is in high precise and steady state with highly efficient. Our proton therapy system was also proven to be in an accurate and reliable condition according to our QA results.


1982 ◽  
Vol 28 (4) ◽  
pp. 908-914 ◽  
Author(s):  
R P Tracy ◽  
R M Currie ◽  
D S Young

Abstract Currently we are using two different ISO-DALT two-dimensional gel electrophoresis systems, designated MC-Iso 1 and MC-Iso 2, for the analysis of serum and plasma samples. Here we report quality-assurance data for both of these systems. CV values for the slopes of the pH gradient (ISO dimension) are 5.6% of less; CV values for the slopes of the molecular-mass curves (log Mr vs relative mobility in the DALT dimension) are 3.4% or less. We examined the various steps of the analysis in detail for reproducibility and protein loss, using radiolabeled albumin, alpha 2-macroglobulin, and beta 2-microglobulin. Generally, in the first dimension, less protein enters the MC-Iso 2 gels (our routine system in which silver stain is used) than enters the MC-Iso 1 gels (our wide-range system for myeloma serum samples, in which the gel is stained with Coomassie Blue), on the average, 87% as much. The CV at this stage for both systems is 5--8%. During equilibration, considerable amounts of protein are lost (approximately 30% in 10 min) from the ISO gel, and the reproducibility is also decreased. Resolution in the DALT dimension has, in most cases, little or no effect on either recovery or reproducibility. Overall, for most proteins expected to appear in an ISO gel of a given pH range, approximately 50--60% of the starting material may be expected to reside in the sodium dodecyl sulfate slab gel, under our conditions. The two most important variables affecting recovery are the concentration of the NaOH (used as catholyte) and the pH of the starting sample. The overall CV for the process is between 8 and 12%.


2013 ◽  
Vol 86 (1031) ◽  
pp. 20130390 ◽  
Author(s):  
K Iqbal ◽  
M Gillin ◽  
P A Summers ◽  
S Dhanesar ◽  
K A Gifford ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document